HOME >> BIOLOGY >> NEWS
University of Pittsburgh scientists find new contributor to aggressive cancers

PITTSBURGH, June 6 -- Mutations in the cell adhesion molecule known as integrin alpha 7 (integrin 7) lead to unchecked tumor cell proliferation and a significantly higher incidence in cancer spread, or metastasis, in several cancer cell lines, report researchers at the University of Pittsburgh School of Medicine in a study being published today in the Journal of the National Cancer Institute. These findings suggest that integrin 7 represents an important new target for cancer therapy and prevention.

Integrin 7 belongs to a major class of cell membrane proteins that play a role in the attachment of a cell to the extracellular matrix (ECM), which is the material that holds cells within a particular type of tissue together. Integrins also help cells attach to one another and are involved in transmitting chemical signals between cells and the ECM.

In this study, the researchers, led by Jianhua Luo, M.D., Ph.D., associate professor in the division of molecular and cellular pathology, University of Pittsburgh School of Medicine, examined whether this gene is mutated in specimens of various human cancers as well as whether the level of integrin 7 expression is associated with clinical relapse of human cancers. They also investigated whether integrin 7 has tumor suppressor activity.

To determine whether mutations in integrin 7 contribute to cancer, Dr. Luo and his collaborators sequenced the integrin 7 genes from 66 human cancer specimens and cell lines representing a number of different kinds of cancer, including cancer of the prostate, liver, brain (glioblastoma) and muscle (leiomyosarcoma).

They found mutations in the integrin 7 gene, particularly those that resulted in an abnormally shortened protein product, or truncation, in 16 of 28 prostate cancers. They also found truncation-inducing mutations in five of 24 liver cancer samples, five of six glioblastomas, and one of four leiomyosarcomas.

Integrin 7 mutations a
'"/>

Contact: Jim Swyers
SwyersJP@upmc.edu
412-647-3555
University of Pittsburgh Schools of the Health Sciences
6-Jun-2007


Page: 1 2 3

Related biology news :

1. NIH gives $8M to University of Pittsburgh School of Medicine for myositis research
2. A study by the MUHC and McGill University opens a new door to understanding cancer
3. Biologists at Tufts University discover 1 reason why chromosomes break, often leading to cancer
4. $9M grant awarded to University of Cincinnati for bipolar disorder research
5. University of Leeds strengthens China links in membrane and neurobiology
6. University of Colorado licenses two influenza virus detection discoveries to Quidel Corp.
7. Manchester University helps with pharaoh DNA analysis
8. University of Cincinnati receives $1.7M to research molecular treatment of brain injury
9. University of Arizona launches major scientific research initiative at Biosphere 2
10. Link between obesity and enlarged heart discovered by University of Arizona researchers
11. Bee researcher at Arizona State University is 1 of 20 new Pew Scholars in the biomedical sciences

Post Your Comments:
(Date:11/3/2014)... , Nov. 3, 2014  NeuroSigma ® , ... life sciences company focused on commercialization of its ... for the treatment of neurological and neuropsychiatric disorders, ... Property has issued a Notice of Allowance for ... is co-owned by NeuroSigma and the Regents of ...
(Date:11/2/2014)... Physics World , James Dacey explores the ways in ... take their innovations from the lab into the commercial ... all start-up companies as they move from prototype to ... main factors: physics-based inventions are usually far from market-ready ... be a lot more complicated than had been originally ...
(Date:11/2/2014)... fascinating to put a flashlight up to our palms ... University in St. Louis engineers are using a similar ... improve imaging of cancerous tissues and to develop potential ... Beare Distinguished Professor of Biomedical Engineering at the School ... time-reversal technology that allows researchers to better focus light ...
Breaking Biology News(10 mins):NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3The 'valley of death' facing physics start-ups 2Improving imaging of cancerous tissues by reversing time 2
(Date:11/26/2014)... Nov. 25, 2014  Roka Bioscience, Inc. (NASDAQ: ... testing solutions for the detection of foodborne pathogens, today announced ... Piper Jaffray  26 th Annual Healthcare Conference on December ... at The New York Palace in New York, ... information concerning the Company, its operations, strategies and prospects may ...
(Date:11/24/2014)... 2014 Five American winners will ... Maktoum Awards for Medical Sciences", in its 8 th ... Emirates , on 15 December 2014. ... The Carter Center which won the Hamdan Award for ... numerous programs that aim to improve health and promote ...
(Date:11/24/2014)... , Nov. 24, 2014 VolitionRx Limited ... tests for cancer and other conditions, today announced that data ... the Science for Business BioWin Day 2014, being held November ... data come from VolitionRx,s lung cancer pilot study, the samples ... Centre Hospitalier Universitaire (CHU) de Liege in Belgium ...
(Date:11/24/2014)... 2014   Veracyte, Inc. (Nasdaq: VCYT ... and chief executive officer, will present in a fireside chat ... Conference on Tuesday, December 2, 2014 at 12:30 p.m. ET ... live audio webcast and subsequent replay may be accessed by ... the website at least 15 minutes prior to the live ...
Breaking Biology Technology:Roka Bioscience to Present at the Piper Jaffray Healthcare Conference 2Five US Winners Among Recipients of Hamdan Medical Awards 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 3VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 4VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 5VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 6Veracyte to Present at the Piper Jaffray 26th Annual Healthcare Conference 2
Cached News: